INTENSITY THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
INTENSITY THERAPEUTICS, INC. (INTS) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $313.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $226.00K.
- INTENSITY THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $87.00K, a 89.95% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$138.00K.
- INTENSITY THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $104.00K.
- INTENSITY THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $360.00K.
- INTENSITY THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$2.27M, a 239.06% decline from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $1.63M, a 131.68% increase from fiscal 2022.
- INTENSITY THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $704.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $226.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $313.00K 10-Q · filed 2026-08-11 | $175.00K derived: sum of 3 quarters · filed 2026-08-11 | $279.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $87.00K 10-Q · filed 2026-05-07 | -$51.00K derived: sum of 2 quarters · filed 2026-05-07 | $53.00K derived: sum of 3 quarters · filed 2026-05-07 | -$419.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$34.00K derived: sum of 2 quarters · filed 2026-03-27 | -$506.00K derived: sum of 3 quarters · filed 2026-08-11 | $360.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$368.00K derived: sum of 2 quarters · filed 2026-08-11 | $498.00K 10-Q · filed 2025-11-06 | -$70.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$472.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $394.00K 10-Q · filed 2026-08-11 | -$174.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $866.00K 10-Q · filed 2026-05-07 | $298.00K derived: sum of 2 quarters · filed 2026-05-07 | -$598.00K derived: sum of 3 quarters · filed 2026-05-07 | $45.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$568.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$1.46M derived: sum of 2 quarters · filed 2026-03-27 | -$821.00K derived: sum of 3 quarters · filed 2026-03-27 | -$2.27M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$896.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$253.00K derived: sum of 2 quarters · filed 2025-11-06 | -$1.70M 10-Q · filed 2025-11-06 | $1.54M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $643.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$804.00K 10-Q · filed 2025-08-07 | $2.44M derived: sum of 3 quarters · filed 2025-08-07 | $93.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.45M 10-Q · filed 2025-05-13 | $1.79M derived: sum of 2 quarters · filed 2025-05-13 | -$550.00K derived: sum of 3 quarters · filed 2025-05-13 | $184.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $897.00K derived: sum of 2 quarters · filed 2025-03-13 | $1.63M derived: sum of 3 quarters · filed 2025-03-13 | $1.63M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$1.61M derived: sum of 2 quarters · filed 2024-11-13 | -$1.61M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $734.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $734.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $704.00K 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |